Pharmacelera Secures €6M to Accelerate Quantum-AI Drug Discovery Platform in US Market
核心洞察
Pharmacelera (搜索) closed a €6 million funding round led by Heran Partners (搜索) to expand its quantum mechanics and AI-powered drug discovery platform in the United States.
The company's proprietary QaiM technology can generate molecules up to 10 times better and 75,000 times faster than traditional AI-led drug discovery approaches.
Pharmacelera (搜索) has already participated in more than 100 projects including notable successes in GPCRs (搜索), serving three big pharma companies and numerous biotechs.
Barcelona-based Pharmacelera (搜索) has closed a €6 million investment round to accelerate expansion into the United States market and enhance its quantum mechanics and artificial intelligence-powered drug discovery platform. The funding round was led by Heran Partners (搜索) and joined by Clave Capital (搜索), Inveready (搜索), and Bio&Tech Smart Capital (搜索).
The deep tech company utilizes proprietary Quantum Mechanics and Artificial Intelligence (QaiM) algorithms to revolutionize drug discovery by identifying novel molecular candidates across the vast chemical "exaSpace" with unprecedented speed and accuracy. According to the company, its technology can generate molecules that are up to 10 times better and 75,000 times faster than traditional AI-led drug discovery approaches.
Quantum-Enhanced Drug Discovery Platform
Pharmacelera (搜索)'s QaiM engine explores the chemical "exaSpace" - potentially comprising trillions of molecules - with capabilities that significantly outperform traditional methods in identifying structurally diverse, novel, and synthesizable compounds. The technology can be applied to small molecules and small peptides across all stages of drug discovery, from hit identification through hit-to-lead to lead optimization.
"The first wave of AI-powered drug discovery promised a lot but delivered comparatively little," said Enric Gibert, Chief Executive Officer of Pharmacelera (搜索). "Pharmacelera is changing the picture, by coupling AI with quantum-based simulations to leverage the exaSpace – the vast, undiscovered universe of trillions of molecules – to find highly novel drug candidates that are up to 10 times better, using a process that's up to 75,000 times faster than traditional AI-led approaches."
Proven Track Record and Customer Base
The company has already participated in more than 100 projects to date, including several notable successes in G-protein-coupled receptors (搜索) (GPCRs (搜索)). Pharmacelera (搜索) has established repeat business relationships with customers in both Europe and the United States, including three big pharma companies and numerous highly-regarded biotechnology firms.
Raf Roelands, Partner at Heran Partners (搜索) and new member of Pharmacelera (搜索)'s Board of Directors, emphasized the validation from existing customers: "By combining physics-based algorithms with machine learning, Pharmacelera enables the design of molecular candidates for novel targets and modes of action with a higher probability of success. We have a high conviction in this company, which was reinforced through direct discussions with its customers, including leading pharmaceutical companies, who have already experienced the significant impact of its technology."
Strategic US Expansion Plans
The investment will primarily support two key growth initiatives: establishing a permanent team in the United States and expanding the technical capabilities of the QaiM drug discovery engine. The US expansion represents a strategic move to strengthen relationships with major pharmaceutical and biotech companies on both the East and West coasts.
"The funding will enable us to establish a team in the U.S. – a natural next step to continue strengthening our relationships with large pharmaceutical and biotech companies on both the East and West coasts," Gibert explained. "It will also help us to greatly widen the capabilities of our QaiM engine."
Strategic Partnerships and Technology Foundation
The funding round follows Pharmacelera (搜索)'s 2023 strategic alliance with Silicon Valley company igniter General Inception (搜索) (GI), where Pharmacelera became GI's AI drug discovery strategic partner. Venkat Reddy, GI's Chief Scientific Officer, sits on Pharmacelera's Board of Directors, and the company's technology has since strengthened the intellectual property of several GI portfolio companies.
Founded by AI engineers, drug hunters from industry, and top academic profiles, Pharmacelera (搜索)'s founders have co-authored more than 500 publications and hold more than 50 patents on technology and drug discovery. The company operates from the Parc Científic de Barcelona, one of Europe's premier life science hubs, and maintains a diversified and scalable business model that has attracted recurrent customers across the pharmaceutical industry.